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the  former type depends mainly on histology (squamous cell 
cancer and adenocarcinoma being the most frequent types), 
clinical and pathological stage, the patient’s comorbidities 
and performance status (2, 3). In contrast, SCLC has a poor 
prognosis and any treatments, whether chemotherapy or ra-
diotherapy or both, have only a palliative intent (4).
Circulating biomarkers are available for lung cancer, but 
none of them are able to replace the role of histology in the 
definition of the pathology – indeed tumor biopsy is mandato-
ry as a first step in lung cancer management. The elevation of 
some serum markers can be observed in both SCLC and NSCLC, 
while others are more associated with specific histopathologi-
cal types. Neuron-specific enolase (NSE) is a valid marker for 
SCLC and its identification by immunohistochemical methods 
in tumor samples is an important step to confirm the diagno-
sis (5). Its accuracy increases with the coexpression of other 
neuroendocrine markers (chromogranin A and synaptophysin) 
and with the absence of epithelial and glandular antigens, 
such as cytokeratins for squamous cell carcinoma and thyroid 
transcription factor 1 (TTF-1) for adenocarcinoma (6). Circulat-
ing NSE can be elevated in cases of SCLC, but its specificity (Sp) 
and sensitivity (Sn) are not sufficient to consider such a marker 
as pathognomonic for diagnosis. A weak predictive role and 
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Introduction
Lung cancer is one of the most common malignant tu-
mors. In recent decades, its incidence has been increasing, 
especially among women, while its mortality rate has shown 
a slight reduction, mainly thanks to surgical and medical im-
provements (1). When approaching a newly detected lung 
cancer, treatments strictly depend on the histological type. 
In particular, an important step to be made is to distinguish 
between non-small cell lung cancer (NSCLC) and small cell 
lung cancer (SCLC). The management and the prognosis of 
ABSTRACT
Background: Recently, pro-gastrin-releasing peptide (pro-GRP) became available as an alternative sensitive, spe-
cific and reliable tumor marker for patients with small cell lung cancer (SCLC), both in limited (LD) and diffuse 
disease (DD).
Methods: We retrospectively analyzed pro-GRP, neuron-specific enolase (NSE) and CEA in patients with SCLC and 
non-small cell lung cancer (NSCLC). Serum pro-GRP level was measured with electrochemiluminescence at our 
laboratory (cutoff 77.8 pg/mL). Continuous variables were analyzed with the Mann-Whitney test, contingency 
data with Fisher’s exact test. Receiver operator characteristic (ROC) curve analysis was performed to identify 
threshold values to set the highest sensitivity (Sn) and specificity (Sp) values.
Results: A total of 65 patients were studied (49 men, median age 67 years, range 27-79). Thirty-seven patients 
had SCLC (29 DD, 8 LD) and 28 advanced NSCLC. Median pro-GRP level was 919 pg/mL (range 22-147,350) in SCLC 
and 32 pg/mL (range 10-119.2) in NSCLC (p<0.0001). NSE was 4.38-fold higher in SCLC patients (p = 0.0005); CEA 
did not reveal significant differences between groups. Pro-GRP Sn and Sp were 86.4% and 96.4%, respectively. 
With ROC curve analysis, a cutoff value of 329.3 pg/mL showed a Sn of 75.8% and Sp of 87.5% in discriminating 
DD from LD. Pro-GRP was not influenced by either liver metastases or renal impairment.
Conclusions: Pro-GRP is sensitive for SCLC diagnosis. Since high marker levels are related to high disease burden, 
pro-GRP may have a negative prognostic significance. Follow-up studies are required to define its role in clinical 
practice in monitoring responses to treatment and early relapses.
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no prognostic significance were reported for this marker when 
evaluated to assess response to chemotherapy (7).
High circulating levels of carcinoembryonic antigen (CEA) 
can be related to lung adenocarcinoma (8) and SCLC (9). 
 However, this marker is more typical of colorectal cancer (10), 
although elevated CEA levels can be observed in many non-
neoplastic conditions as well (11).
Another marker observed in lung cancer patients is CY-
FRA21-1, a peptidic fragment of cytokeratin-19. This peptide 
can be elevated in sera of NSCLC patients, but has a limited 
clinical utility in SCLC (12). Both CEA and CYFRA21-1 have 
been shown to have a predictive role in monitoring response 
to therapies for NSCLC (13). The identification of biomarkers 
having an analogous role for SCLC is still an unmet clinical 
need. Pro-gastrin-releasing peptide (pro-GRP) is an emerg-
ing circulating biomarker useful in SCLC diagnosis (14-16). 
It is the precursor of gastrin-releasing peptide (GRP), an ac-
tive hormone involved in the physiological digestive process. 
GRP has shown mitogenic activity in vitro for SCLC, but not 
for squamous cell cancer or adenocarcinoma of the lung (17). 
GRP, the direct derivative of pro-GRP, might act as an auto-
crine growth factor for SCLC cells and GRP receptor mRNA is 
found in two fifths of cases of SCLC (18). The first identifica-
tion of GRP in lung cancer specimens was in 1983. Its main 
limitation is its short half-life of approximately 2 minutes (19). 
Therefore laboratory assays have been developed in recent 
decades to identify its precursor pro-GRP, which is much 
more stable (20).
Many laboratory studies and patient series have been re-
ported so far, but few data are available about the accuracy of 
pro-GRP in day-to-day clinical practice. The aim of this study 
was to evaluate single-center records of this validated marker 
in white patients. This paper discusses those results, with an 
overview of the literature.
Methods
Patient selection
This was a retrospective analysis of patients treated at our 
center for advanced lung cancer. Advanced disease was de-
fined as the presence of unresectable or locally advanced or 
metastatic disease not amenable to locoregional treatments, 
in particular surgery and radiotherapy. Serum pro-GRP was 
measured in all patients with a newly diagnosed advanced 
lung cancer who were hospitalized in our Medical Oncology 
Unit from December 2014 to January 2017. CEA and NSE 
were measured in all patients as well.
Assay description
Serum pro-GRP, CEA and NSE were measured by an elec-
trochemiluminescence immunoassay using a Roche C6000 
automated analyzer (Roche Diagnostics GmbH, Penzberg, 
Germany). For pro-GRP, the reference range was set as the in-
terval between 0 and 77.8 pg/mL (77.8 pg/mL was the 97.5th 
percentile of serum pro-GRP concentration in 698 healthy 
white adults, as described in Roche studies No. RD001525 
and RD000788 and as reported on the product sheet of the 
automated analyzer) (21). CEA and NSE were considered 
 positive if their serum levels were higher than 5 ng/mL (9) 
and 16.3 ng/mL (22), respectively.
Statistical analysis
To calculate Sn, Sp, positive and negative predictive values 
(PPV and NPV, respectively), the following conditions were 
considered: SCLC with elevated marker as true positive (TP), 
NSCLC with normal marker as true negative (TN), SCLC with 
normal marker as false negative (FN) and NSCLC with elevat-
ed marker as false positive (FP). The same analysis was per-
formed to discriminate limited (LD) from diffuse SCLC disease 
(DD). Supplementary Table I reports the definitions used for 
calculations (available online at www.biological-markers.com – 
Definitions used to calculate sensitivity, specificity, positive and 
negative predictive values). The diagnostic odds ratio was cal-
culated as a statistical tool combining both Sn and Sp in a single 
indicator (23). Receiver operating characteristic (ROC) curve 
analysis was completed to define threshold values for pro-GRP. 
The area under the ROC curve (AUC) was estimated, to quan-
tify the overall accuracy of pro-GRP levels and their Sn and Sp.
Univariate analyses were performed to assess the role of 
liver metastases and renal impairment as potential confound-
ers of serum pro-GRP levels. In all cases, categorical data were 
analyzed with chi-squared or Fisher’s exact test and continu-
ous variables with the Mann-Whitney U test. Threshold for 
statistical significance was set at 0.05. Statistical analyses 
were performed with GraphPad Prism®, version 5.02.
Results
Patient characteristics
A total of 65 patients were analyzed: 37 patients with 
SCLC and 28 with locally advanced or metastatic NSCLC. All 
patients were Caucasian, three quarters of them were men, 
with a median age of 68 years. Patients’ characteristics are 
summarized in Supplementary Table II (available online at 
www.biological-markers.com – Patient characteristics). In the 
majority of NSCLC patients (86%) disease stage was IV accord-
ing to the American Joint Committee on Cancer classification 
(8th edition of the AJCC staging manual), while in the remain-
ing 4 patients, tumor extension was locally advanced. Pro-
GRP was measured in all patients. NSE values were available 
for 51 subjects (32 SCLC + 19 NSCLC), CEA for 43 (28 SCLC + 
15 NSCLC).
SCLC vs. NSCLC
Median pro-GRP was 67 pg/mL (range 10-147,350) in the 
total study population, 919 pg/mL (range 22-147,350) in pa-
tients with SCLC and 32 pg/mL (range 10-119) in those affect-
ed by NSCLC (p<0.0001). In SCLC patients, median NSE was 
4.38-fold higher than in NSCLC patients (p = 0.0005). Median 
CEA was 8.02 ng/mL (range 1.01-1,767) in SCLC and 9 ng/mL 
(range 0-241) in NSCLC (p = 0.98). Figure 1 summarizes the 
results on a logarithmic scale.
Considering local cutoff values for positivity (77.8 pg/mL), 
pro-GRP Sn, Sp and accuracy in SCLC were 86.49%, 96.43% 
and 90.77%, respectively. Accuracy was 72.55% for NSE (Sn 
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75%, Sp 68.42%), 46.51% for CEA (Sn 57.14%, Sp 26.67%). 
These results are summarized in Supplementary Table III 
(available online at www.biological-markers.com – Pro-GRP 
sensitivity, specificity and accuracy in SCLC). On ROC curve 
analysis, the AUC was 0.93 (95% confidence interval [95% CI], 
0.87-0.99) for pro-GRP in SCLC (p<0.0001). The serum value 
showing the highest likelihood ratio (22.7), thus potentially 
being a reliable threshold value, was 71.9 pg/mL. At this 
marker concentration, Sn was 81% (95% CI, 64.8%-92%) and 
Sp 96.4% (95% CI, 81.6%-99.9%). NSE and CEA AUCs were 
0.79 (95% CI, 0.67-0.91) and 0.5 (95% CI, 0.31-0.68), respec-
tively (Fig. 2). Five SCLC patients had normal pro-GRP values, 
thus they were considered as FNs. Four of them had elevated 
NSE (median NSE 13.9 ng/mL, range 7.9-71.3) and two thirds 
(CEA not available for 2 cases) had elevated CEA (median CEA 
6.07 ng/ml, range 1.4-9.6). In particular, 2 patients had both 
positive markers, CEA and NSE were both negative in 1 pa-
tient and in the remaining 2 patients with elevated NSE, CEA 
results were not available.
Excluding patients with locoregional disease (8 with LD 
SCLC and 4 with NSCLC with unresectable locally advanced 
disease), the differences between pro-GRP values were sta-
tistically significant (p<0.0001). In fact, median pro-GRP was 
2,659 pg/mL (range 31.6-147,350) in metastatic SCLC patients 
(n = 29) and 34.85 pg/mL (range 9.5-119.2) in NSCLC patients 
(n = 24) with metastatic disease.
Diffuse vs. limited disease in SCLC
Among SCLC patients, 29 suffered from DD and 8 from LD. 
Considering all of the limitations of a statistical analysis con-
ducted over a small-size population, median pro-GRP was 46-
fold higher (Fig. 3) in the former group (DD 2,659 pg/ml, range 
31.6-147,350; LD 57.85 pg/mL, range 22-3702). This difference 
was statistically significant (p = 0.004). Median NSE and CEA 
values were higher in patients with metastatic disease than in 
those with locoregional tumors, but no statistically significant 
differences were observed (p = 0.12, for NSE; p = 0.3, for CEA).
The same data were confirmed by ROC curve analysis as 
well. AUC was 0.83 (95% CI, 0.67-0.99) for pro-GRP in DD (p = 
0.004). On ROC curve analysis, a threshold value of 329.3 pg/mL 
showed the highest likelihood ratio (6.07) in discriminating LD 
from DD. At this value, Sn was 75.8% (95% CI, 56.4%-89.7%) 
and Sp 87.5% (95% CI, 47.3%-99.6%).  Using the validated 
threshold value of 77.8 pg/mL (see “Methods”), Sn and Sp for 
pro-GRP in discriminating DD from LD were 93.1% and 62.5%, 
Fig. 1 - Serum marker values (small cell lung cancer [SCLC] vs. non-small cell lung cancer [NSCLC]). CEA = carcinoembryonic antigen; NSE = 
neuron-specific enolase; pro-GRP = pro-gastrin-releasing peptide.
Fig. 2 - Receiver operator characteristic (ROC) curve analysis for markers small cell lung cancer (SCLC) vs. non-small cell lung cancer (NSCLC). 
AUC = area under the curve; CEA = carcinoembryonic antigen; NSE = neuron-specific enolase; pro-GRP = pro-gastrin-releasing peptide.
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Fig. 3 - Serum marker values (diffuse [DD] vs. limited disease [LD] in small cell lung cancer [SCLC]). CEA = carcinoembryonic antigen; NSE = 
neuron-specific enolase; pro-GRP = pro-gastrin-releasing peptide.
respectively. These values were  inferior for both NSE and CEA 
(Suppl Tab. IV, available online at www.biological-markers.
com – Sensitivity and specificity for pro-GRP, NSE and CEA, in 
discriminating DD from LD).
Serial marker measurements
Serial measurements of serum pro-GRP levels were avail-
able for 19 patients (Fig. 4). The first data point is the base-
line measurement, the following values were measured at 
each hospitalization for chemotherapy. Therefore, each point 
corresponds to a chemotherapy cycle. Figure 4A, 4B and 4C 
reports the serial measurement of responders, patients with 
stable disease and non responding patients, respectively. In 
most cases an initial reduction was observed after the start 
of chemotherapy. With stable disease, no significant marker 
fluctuations were seen and in all patients disease progression 
was accompanied by pro-GRP elevation. Median reduction 
from baseline pro-GRP to first measurement after chemo-
therapy start was 0.24 (range −1.09 to 2.8). In 3 cases, a Log10 
reduction was observed after systemic treatment and in 1 out 
of these 3 subjects a 664-fold reduction was observed (from 
147,350 to 221.8 pg/mL).
Confounding factors
Considering the total study population in a pooled man-
ner, 19 patients had liver metastases (14 SCLC, 5 NSCLC). 
 Renal function was reduced in 12 subjects (9 SCLC, 3 
NSCLC). No significant roles of potentially confounding fac-
tors were observed. Pro-GRP was similar in both men and 
women (p = 0.34) and did not vary according to age (p = 
0.61). Median pro-GRP was 5.8-fold higher in patients with 
liver metastases than in those without hepatic disease, but 
the difference was statistically not significant (p = 0.32) and 
the AUC identified by ROC curve analysis was 0.59. Patients 
with a reduced renal function (defined as an estimated 
glomerular filtration rate [eGFR] <90 mL/min per body sur-
face area [BSA], calculated with the Chronic Kidney Disease 
 Epidemiology Collaboration [CKD-EPI] formula) had a slight-
ly higher median pro-GRP value (1.35-fold higher), but also 
in this case, the difference was not statistically significant 
(p = 0.45, AUC = 0.58).
Discussion
Pro-GRP accuracy in SCLC was described for the first time 
in 1995, when this marker, measured with enzyme-linked 
 immunosorbent assay, was reported to be higher in SCLC 
than in benign pneumopathies and in NSCLC (20).
The higher Sn and Sp of this marker in SCLC, in comparison 
with NSE, were confirmed by more recent studies as well (24). 
A better accuracy in the diagnosis of SCLC was reported for 
pro-GRP compared with NSE. Our data are in line with such 
results. Nonetheless, due to the scarcity of perspective data, 
to date the role of NSE cannot be superseded by pro-GRP.
In Bayesian statistics, we are used to thinking of a true 
negative as an event in which the study participant is a healthy 
control and the variable being studied is also negative. Even 
though the way we exploited to calculate sensitivity, specific-
ity, PPV, NPV and also to discriminate between LD and DD is 
not usual, we considered only lung cancer patients in order to 
better adhere to a real life medical oncology clinical practice. 
Indeed, it is infrequent that such biomarkers could be used in 
an extra-oncologic setting.
The Sn of this marker was much higher in our population 
than that reported in the literature (86% vs. 47%), while the Sp 
was comparable (25). Likely, patient selection bias could have 
influenced such results. Indeed, all patients in exam were af-
fected by lung cancer and we considered as true negative 
only NSCLC patients with low marker values. On the contrary, 
to validate pro-GRP accuracy, literature reports analyzed as 
control population patients with benign lung diseases, such 
as sarcoidosis, chronic obstructive pulmonary disease and 
primary pulmonary fibrosis. In such a setting, to discriminate 
between SCLC and cancer-free patients, a lower cutoff level 
(34.2 pg/mL) was defined (26).
Another study showed higher threshold values for posi-
tivity (50 pg/mL), reporting that median serum values were 
<80 pg/mL in benign lung diseases and <120 pg/mL in patients 
with non lung and non neuroendocrine cancers (27). The cut-
off value for pro-GRP positivity used in our laboratory and in 
this study was 77.8 pg/mL. Considering the ROC curve analysis 
results, 71.9 pg/mL could be seen as a better threshold value 
to discriminate SCLC from NSCLC. The AUC and the diagnostic 
odds ratio revealed the robustness of pro-GRP in discriminat-
ing SCLC from NSCLC. Among the 3 tested markers, pro-GRP 
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Fig. 4 - Serial measurements of serum pro-GRP in 19 small cell lung 
cancer (SCLC) patients (Log10 scales): (A) patients with response 
to therapy (n = 6); (B) patients with stable disease (n = 10); and (C) 
patients with disease progression (n = 3).
had the highest AUC and diagnostic odds ratio, followed by 
NSE and CEA.
Among the 5 SCLC patients with normal pro-GRP (FN), 3 
were affected by LD and 2 had oligometastatic disease. Due 
to the NSE positivity in of 4 of these 5 cases, NSE should be 
used as complementary marker, as already suggested by oth-
er authors, while skepticism about the utility of CEA remains 
when both NSE and pro-GRP evaluations are performed (28).
A limitation of our study was the low statistical power 
due to the small sample size. Nonetheless, we used statisti-
cal methods to find any differences between LD and DD to 
have just an outline of what is intuitively observed in day-
to-day clinical practice – that is, an even apparent correla-
tion between tumor burden and marker levels. The results 
of our analysis are, of course, preliminary, because a cor-
rect statistical analysis could not be performed using our 
sample size.
The only NSCLC patient with a high pro-GRP level 
(119.2 pg/mL) was affected by a poorly differentiated lung 
adenocarcinoma with a high burden of metastatic disease 
(FP). In this patient, CEA was higher than the upper reference 
limit (8.59 ng/mL), while NSE was normal (3.1 ng/mL).
In the setting of SCLC, no role for pro-GRP in predicting 
distant metastasis has been described so far, therefore the 
measurement of such a marker should avoided in this setting 
at baseline (29). On the other hand, some roles in predicting 
neurological events and survival were found for pro-GRP in 
patients undergoing prophylactic cranial irradiation (30).
Our data suggest that a serum pro-GRP higher than 
329.3 pg/mL might have a satisfactory Sp with a modest Sn in 
helping to differentiate DD from LD SCLC. These data can be 
interpreted as showing that vast tumor burdens could be re-
lated to higher pro-GRP production. Therefore, the accuracy 
of such a marker is comparable to that shown in reports in 
the scientific literature (31).
Within the limitations of a retrospective analysis, we ob-
served that pro-GRP levels were related to disease natural his-
tory. Indeed, we observed marker increases in case of disease 
progression, reductions in case of response to treatments 
and fluctuations in case of stable disease. In an Asian case 
series considering 82 patients with unselected lung cancer 
(both SCLC and NSCLC), pro-GRP was reduced after chemo-
therapy start, but the biomarker’s accuracy was not validated 
(32). On the other hand, both serum pro-GRP and NSE failed 
to be established as markers for detecting relapses before the 
onset of overt clinical or radiographic findings (33). Perspec-
tive studies with white patients confirmed these results (34). 
In another case series, the most reliable circulating marker 
in monitoring response to treatments was pro-GRP, because 
NSE, CYFRA 21-1 and lactate dehydrogenase levels fluctuate 
during systemic therapies (35).
A recent study described the role of both pro-GRP and 
NSE not only in monitoring treatment response, but also in 
predicting patients’ survival (36). An association with survival 
was reported with univariate analysis of limited SCLC (37). A 
retrospective analysis showed that pro-GRP revealed a higher 
correlation to tumor shrinkage and to prognosis than NSE 
(38). It is possible that the correlation between this marker 
and survival can be due to underlying massively extended dis-
ease and/or high disease burden.
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The role of chronic kidney failure in altering serum bio-
markers has been reported, notably for CYFRA21-1 and 
 pro-GRP (39). Nonetheless, within the limitations of a low 
statistical power, our data showed that neither the presence 
of liver metastases nor a concomitant renal impairment influ-
enced pro-GRP levels in SCLC patients. An eGFR of 60 mL/min 
per BSA is the usual cutoff value used to define an impaired 
renal function. We deliberately chose to set it at 90 mL/min 
per BSA, to test differences in pro-GRP values between people 
with a normal blood creatinine and patients with any modest 
renal damage. It is likely that higher pro-GRP values observed 
in patients with liver metastases, even though not statistically 
significant, could be related to higher systemic disease bur-
den rather than a reduced pro-GRP altered metabolism.
As reported before, pro-GRP products, notably GRP, are 
able to induce cell progression in SCLC. Recent studies re-
vealed that GRP down-regulation is able to reduce SCLC 
growth and to increase tumor cell apoptosis. Therefore, since 
GRP inhibition could constitute a theoretical target for can-
cer treatments, further study evaluating the role of pro-GRP 
should be conducted (40).
Conclusion
Our data and review of the literature showed that pro-GRP 
can be considered as an affordable and accurate biomarker in 
the diagnosis of SCLC and a useful tool to discriminate SCLC 
from NSCLC. Due to our small sample size, no inferences can 
be made in discerning DD from LD. The Sn and Sp of pro-GRP 
are higher than those for NSE and CEA. Its utility in monitor-
ing treatment response is confirmed by literature data. An 
interesting point to be clarified in the future would be the 
investigation of this biomarker in monitoring the response to 
new therapeutic agents.
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